Artificial Sweeteners Disrupt Gut Microbiome and Increase Glucose Intolerance: 120,000-Person Cohort Study

Do Artificial Sweeteners Cause Glucose Intolerance?

The relationship between artificial sweeteners and glucose intolerance has been established through multiple lines of evidence. A landmark 2014 study published in Nature by Suez, Elinav, and colleagues at the Weizmann Institute of Science demonstrated that non-caloric artificial sweeteners — particularly saccharin — induced glucose intolerance in mice by altering the gut microbiota, and confirmed these effects in a small human cohort. When gut bacteria from sweetener-exposed mice were transplanted into germ-free mice, the recipients developed glucose intolerance, establishing a causal role for the microbiome.

In 2022, the same research group published a rigorous randomized controlled trial in Cell involving 120 healthy adults who had not previously consumed artificial sweeteners. Participants were assigned to consume sucralose, aspartame, saccharin, stevia, or glucose (controls) for two weeks. Both sucralose and saccharin significantly impaired glycemic responses compared to controls, with effects that were detectable within days. Notably, aspartame and stevia did not produce statistically significant glycemic impairment in this trial, though all four sweeteners distinctly altered gut microbiome composition. Large prospective cohort studies, including data from the French NutriNet-Santé cohort (over 100,000 participants), have further associated higher artificial sweetener intake with increased risk of type 2 diabetes and cardiovascular disease, though these observational findings cannot prove causation on their own.

How Do Artificial Sweeteners Affect the Gut Microbiome?

The 2022 Cell trial provided some of the most detailed human microbiome data on this topic. Using shotgun metagenomic sequencing and metabolomic profiling, researchers found that each of the four tested sweeteners produced a distinct microbiome signature. Sucralose and saccharin consumers showed the most metabolically relevant changes, including shifts in microbial species involved in short-chain fatty acid production and carbohydrate metabolism. Importantly, the researchers demonstrated that the glycemic effects were microbiome-dependent: fecal transplants from human sweetener consumers into germ-free mice replicated the glucose intolerance phenotype, confirming the microbiome as a mediating mechanism.

Earlier mechanistic research has identified several pathways by which sweetener-driven dysbiosis may promote metabolic dysfunction. Depletion of beneficial taxa such as Bifidobacterium and Akkermansia muciniphila — bacteria important for mucin production and intestinal barrier maintenance — has been observed in both animal and human studies. This can lead to increased intestinal permeability and higher circulating levels of bacterial lipopolysaccharide (LPS), a potent trigger of low-grade systemic inflammation. Reduced production of short-chain fatty acids, particularly butyrate, may further impair GLP-1 signaling and glucose homeostasis. The WHO cited this emerging evidence in its 2023 conditional recommendation against the use of non-sugar sweeteners for weight management, noting potential increased risks of type 2 diabetes and cardiovascular disease with long-term use.